

Global HPV Vaccine Introduction Overview


Projected and current national introductions, demonstration/pilot projects, gender-neutral vaccination programs, and global HPV vaccine introduction maps (2006-2023)

Updated 17 Mar 2022



Global HPV Vaccine Introduction

Year:
2022




- Introduction status**
- National
 - Subnational
 - Demo complete*
 - Projected - national

* Decision pending on
national introduction

As of 17 Mar 2022

Global HPV Vaccine Introductions by World Bank Category




World Bank Category (2021)

LIC	8 of 29 have introduced
LMIC	22 of 51 have introduced
UMIC	39 of 61 have introduced
HIC	75 of 84 have introduced
Not classified	


As of 17 Mar 2022

HPV Vaccine Introduction Status in Gavi Countries Eligible for HPV Support



As of 17 Mar 2022

Burden of Disease in Countries with National HPV Vaccination




Mortality rate (ASR)*

<5
5 - 14.9
15 - 29.9
≥ 30

*rates per 100,000 women per year;
estimated 2020 cervical cancer
mortality rates from IARC Globocan
data

As of 17 Mar 2022

Burden of Disease in Countries **without** National HPV Vaccination



Mortality rate (ASR)*

<5
5 - 14.9
15 - 29.9
≥30

*rates per 100,000 women per year;
estimated 2020 cervical cancer
mortality rates from IARC Globocan
data

As of 17 Mar 2022

Countries and territories with HPV vaccine on national routine immunization schedule

WHO Member States (n=122 active; n=3 stopped)

WHO Member States (n=122 active; n=3 stopped)	Non-members (n=27)
Andorra (2014)	Czech Republic (2012)
Antigua & Barbuda (2018)	Denmark (2008)
Argentina (2011)	Dominica (2019)
Armenia * (2018)	Dominican Republic (2017)
Australia (2007)	Ecuador (2014)
Austria (2008)	El Salvador (2020)
Bahamas (2015)	Estonia (2018)
Barbados (2014)	Ethiopia * (2018)
Belgium (2007)	Federated States of Micronesia (2009)
Belize (2016)	Fiji † (2008-09, stopped 2010; 2013)
Bhutan * (2010)	Finland (2013)
Bolivia * (2017)	France (2006)
Botswana * (2015)	The Gambia (2019) *†
Brazil * (2014)	Georgia (2019)
Brunei (2012)	Germany (2007)
Bulgaria (2012)	Greece (2008)
Cameroon (2020)	Grenada (2019)
Canada (2007)	Guatemala (2018)
Cape Verde (2021)	Guyana *† (Subnational 2012-13; 2017)
Chile (2014)	Honduras (2016)
Colombia † (2012)	Hungary (2014)
Cook Islands (2011)	Iceland (2011)
Costa Rica (2019)	Indonesia (2019)
Côte d'Ivoire * (2019)	Ireland (2010)
Croatia (2016)	Israel (2013)
Cyprus (2016)	Italy (2008)
Jamaica (2017)	Japan (2011)
Kazakhstan (subnational 2013-2015; stopped 2015)	Niue (2019)
Kenya * (2019)	Norway (2009)
Lao PDR * (2020)	Palau (2008)
Lesotho * (2012, stopped 2015)	Panama † (2008)
Latvia (2010)	Paraguay (2013)
Liberia * (2019)	Peru * (2011, stopped 2012; 2014)
Libya (2014)	Philippines † (2015)
Lithuania (2016)	Portugal (2008)
Luxembourg (2008)	Qatar (2020)
Macedonia FYR (2009)	Romania (2009-10, stopped 2011)
Malawi * (2019)	Rwanda (2011)
Malaysia (2010)	Samoa (2021)
Maldives (2019)	San Marino (2008)
Malta (2012)	Sao Tome And Principe * (2021)
Marshall Islands § (2009)	Senegal * (2018)
Mauritania (2021)	Seychelles (2014)
Mauritius (2016)	Singapore (2010)
Mexico † (subnational 2008-2011; 2012)	Slovenia (2009)
Moldova * (2020)	Solomon Islands * (2019)
Monaco (2011)	South Africa * (2014)
Morocco (2021)	South Korea (2016)
Mozambique * (2021)	Spain (2007)
Myanmar (2020)	Sri Lanka (2017)
Nauru (2021)	St. Kitts and Nevis (2019)
St. Lucia (2019)	
St. Vincent and the Grenadines (2017)	
Suriname (2013)	
Sweden (2012)	
Switzerland (2008)	
Tanzania * (2018)	
Thailand * (2017)	
Trinidad & Tobago (2012, stopped 2013; 2015)	
Turkmenistan (2016)	
Tuvalu (2021)	
Uganda *† (2015)	
United Arab Emirates † (subnational 2008-2012; 2013)	
United Kingdom (2008)	
United States (2006)	
Uruguay (2013)	
Uzbekistan * (2019)	
Zambia * (2019)	
Zimbabwe * (2018)	

* National/territorial introduction has followed pilot.

† National/territorial introduction in phases, either based on geography, target population, or both.

As of 17 Mar 2022

Countries and territories with gender-neutral HPV vaccination schedules (year of recommendation)

WHO Member States (n=39)		Non-members (n=13)
Antigua and Barbuda (2018)	Israel (2015)	American Samoa † (2014)
Argentina (2017)	Italy (2018*)	Bermuda (2016)
Australia (2013)	Luxembourg (2019)	Gibraltar †
Austria (2014)	Netherlands (2009)	Guam † (2011)
Bahamas (2015)	New Zealand (2017)	Greenland †
Barbados (2017)	Niue (2019)	Guernsey †
Belgium (2019)	Norway (2018)	Isle of Man †
Bhutan (2020)	Panama (2016)	Jersey †
Brazil (2017)	Portugal	Liechtenstein (2016)
Canada (2017*)	St. Kitts and Nevis (2019)	Northern Mariana Islands † (2011)
Chile (2019)	St. Lucia (2019)	Niue (2019)
Croatia (2016)	Sweden (2019)	Puerto Rico †
Czech Republic (2016)	Switzerland (2016)	U.S. Virgin Islands †
Denmark (2019)	Turkmenistan (2016)	
Dominica (2019)	Trinidad and Tobago (2015)	
France (2020)	United Kingdom (2019)	
Germany (2019)	United States (2011)	
Guyana (2019)	Uruguay (2019)	
Hungary		
Ireland (2019)		
Israel (2015)		

* province or region specific
† territory

As of 17 Mar 2022

Countries or territories with completed HPV vaccine pilot or demonstration project (year/sponsor)

Angola (2014-2015 donation)	Georgia (2010-2014 GAP; 2017-2018 Gavi)	Moldova (2010-2011 GAP; 2017-2018 Gavi)	Togo (2015-2017 Gavi)
Armenia (2017-2018 Gavi)	Ghana (2013 GAP; 2013-2015 Gavi)	Mongolia (2012; 2014 GAP)	Uganda (2008-2011 PATH; 2010 GAP; 2012-2014 Merck)
Bangladesh (2016-2017 Gavi)	Guyana (2012-2013 GAP)	Mozambique (2014-2016 Gavi)	Uzbekistan (2009 GAP)
Benin (2015-2016 Gavi)	Haiti (2009 GAP)	Nepal (2008; 2010-2014 ACCF/GAP; 2015-2017 Gavi)	Vanuatu (2009-2018 ACCF)
Bhutan (2009 GAP)	Honduras (2011-2014 GAP)	Niger (2014-2016 Gavi)	Vietnam (2008-2010 PATH)
Bolivia (2009-2011 GAP)	India (2009-2010 PATH)	Papua New Guinea (2012 GAP)	Zambia (2013-2014 GAP; 2015 Merck)
Botswana (2013 World Bank; 2014 MOH)	Indonesia (2013; 2017-2018 Gavi)	Peru (2007-2008; 2009-2010 PATH)	Zimbabwe (2015-2017 Gavi)
Brazil (2010-2013 GAP)	Kenya (2011 GAP; 2013-2015 Gavi)	Philippines (2010 JHU)	
Burkina Faso (2015-2017 Gavi)	Kiribati (2011-2013 ACCF/GAP)	Sao Tome e Principe (2017-2018 Gavi)	
Burundi (2015-2016 Gavi)	Lao PDR (2013-2016 Gavi)	Senegal (2015-2018 Gavi)	
Cambodia (2009-2011 GAP; 2016-2017 Gavi)	Lesotho (2009-2011 GAP)	Sierra Leone (2013-2014 Gavi)	
Cameroon (2010 GAP; Nov 2014-2016 Gavi)	Liberia (2016 Gavi)	Solomon Islands (2015-2017 Gavi)	
Cote d'Ivoire (2015-2017 Gavi)	Madagascar (2013-2015 Gavi)	South Africa (2010-2011; 2013 donations)	
Ethiopia (2015-2017 Gavi)	Malawi (2013-2016 Gavi)	Tanzania (2010-2011 GAP/LSHTM; 2014-2017 Gavi)	
The Gambia (2015-2017 Gavi)	Mali (2012 GAP; 2015-2017 Gavi)	Thailand (2010 JHU)	

52 countries conducted pilots or demonstration projects.

As of 17 Mar 2022

Countries or territories projected to add HPV vaccine to routine immunization schedule

2022	
Burkina Faso *	Samoa
Curacao	Sierra Leone *
Eritrea *	Tokelau
eSwatini	Tonga
Kyrgyzstan	Tuvalu
Lesotho *	Vanuatu *
Nicaragua	

2023	
Afghanistan	Mongolia *
Bangladesh *	Nepal *
Benin *	Niger *
Burundi *	Nigeria
Cambodia *	Papua New Guinea *
Djibouti	Republic of Congo
Ghana *	Timor-Leste
Mali *	Togo *

BOLD signifies the country was already approved for introduction by Gavi


* National/territorial introduction will follow pilot.

29 additional countries and territories are projected to have HPV vaccine on national schedule by the end of 2023.

As of 17 Mar 2022

Global HPV Vaccine Introduction

Year:
2006



Introduction status


- Demonstration
- National
- Subnational
- Demo complete*

* Decision pending on national introduction

As of 17 Mar 2022

Global HPV Vaccine Introduction

Year:
2007



Introduction status


- Demonstration
- National
- Subnational
- Demo complete*

* Decision pending on national introduction

As of 17 Mar 2022

Global HPV Vaccine Introduction

Year:
2008



Introduction status


- Demonstration
- National
- Subnational
- Demo complete*

* Decision pending on
national introduction

As of 17 Mar 2022

Global HPV Vaccine Introduction

Year:
2009



Introduction status


- Demonstration
- National
- Subnational
- Demo complete*

* Decision pending on
national introduction

As of 17 Mar 2022

Global HPV Vaccine Introduction

Year:
2010



Introduction status


- Demonstration
- National
- Subnational
- Demo complete*

* Decision pending on national introduction

As of 17 Mar 2022

Global HPV Vaccine Introduction

Year:
2011



Introduction status


- Demonstration
- National
- Subnational
- Demo complete*

* Decision pending on national introduction

As of 17 Mar 2022

Global HPV Vaccine Introduction

Year:
2012



Introduction status


- Demonstration
- National
- Subnational
- Demo complete*

* Decision pending on national introduction

As of 17 Mar 2022

Global HPV Vaccine Introduction

Year:
2013



Introduction status


- Demonstration
- National
- Subnational
- Demo complete*

* Decision pending on national introduction

As of 17 Mar 2022

Global HPV Vaccine Introduction

Year:
2014



Introduction status


- D Demonstration
 - N National
 - S Subnational
 - C Demo complete*

* Decision pending on national introduction

As of 17 Mar 2022

Global HPV Vaccine Introduction

Year:
2015



Introduction status


- Demonstration
- National
- Subnational
- Demo complete*

* Decision pending on national introduction

As of 17 Mar 2022

Global HPV Vaccine Introduction

Year:
2016



Introduction status


- Demonstration
- National
- Subnational
- Demo complete*

* Decision pending on national introduction

As of 17 Mar 2022

Global HPV Vaccine Introduction

Year:
2017



Introduction status


- Demonstration
- National
- Subnational
- Demo complete*

* Decision pending on
national introduction

As of 17 Mar 2022

Global HPV Vaccine Introduction

Year:
2018



Introduction status


- Demonstration
- National
- Demo complete*

* Decision pending on
national introduction

As of 17 Mar 2022

Global HPV Vaccine Introduction

Year:
2019



Introduction status


- Demonstration
- National
- Subnational
- Demo complete*

* Decision pending on
national introduction

As of 17 Mar 2022

Global HPV Vaccine Introduction

Year:
2020



Introduction status


- National
- Subnational
- Demo complete*

* Decision pending on
national introduction

As of 17 Mar 2022

Global HPV Vaccine Introduction

Year:
2021



Introduction status


- National
- Subnational
- Demo complete

* Decision pending on
national introduction

As of 17 Mar 2022

Global HPV Vaccine Introduction

Year:
2022



Introduction status


- National
- Subnational
- Demo complete*
- Projected - national

* Decision pending on
national introduction

As of 17 Mar 2022

Global HPV Vaccine Introduction

Year:
2023



Introduction status

- National
- Subnational
- Demo complete*
- Projected - national

* Decision pending on
national introduction

As of 17 Mar 2022